Corticosteroid phobia (corticophobia) in parents of young children with atopic dermatitis and their health care providers

Pediatric Dermatology, EarlyView.
Source: Pediatric Dermatology - Category: Dermatology Authors: Source Type: research

Related Links:

Publication date: Available online 19 September 2019Source: The LancetAuthor(s): Claus Bachert, Joseph K Han, Martin Desrosiers, Peter W Hellings, Nikhil Amin, Stella E Lee, Joaquim Mullol, Leon S Greos, John V Bosso, Tanya M Laidlaw, Anders U Cervin, Jorge F Maspero, Claire Hopkins, Heidi Olze, G Walter Canonica, Pierluigi Paggiaro, Seong H Cho, Wytske J Fokkens, Shigeharu Fujieda, Mei ZhangSummaryBackgroundPatients with chronic rhinosinusitis with nasal polyps (CRSwNP) generally have a high symptom burden and poor health-related quality of life, often requiring recurring systemic corticosteroid use and repeated sinus sur...
Source: The Lancet - Category: General Medicine Source Type: research
Authors: Ewy S, Pham H, Quan K, Su B, Tachdjian R Abstract Bullous pemphigoid (BP) is a rare blistering skin disease that is commonly treated with corticosteroids and immunosuppressive agents. Here, we present a 74-year-old woman with severe BP following a leg fracture who was successfully treated with omalizumab. We started her on a regimen of omalizumab 300 mg subcutaneously every 4 weeks, and within a week she reported significantly decreased pain and faster healing time of lesions. Incidentally, bilateral erythematous, non-blistering dermatitis developed 5 centimeters distal to the injection sites within a week...
Source: Journal of Drugs in Dermatology - Category: Dermatology Tags: J Drugs Dermatol Source Type: research
CONCLUSIONS: These results demonstrated the safety and efficacy of using the investigational body wash formulas with lipids in reducing the needs for corticosteroid and improving the healthy composition of skin microbiome vs. the mild synthetic bar soap. PMID: 31512226 [PubMed - as supplied by publisher]
Source: The Australasian Journal of Dermatology - Category: Dermatology Authors: Tags: Australas J Dermatol Source Type: research
In phase 3 dupilumab (DPL) trials, the overall severity of 4 signs of atopic dermatitis (AD), erythema, infiltration/papulation, excoriation lichenification, was assessed globally through the investigator-assessed Global Individual Signs Score (GISS; range 0 –12). The effects of DPL on AD signs as measured by GISS in phase 3 trials are reported (LIBERTY AD: SOLO 1&2 [pooled] - NCT02277743/NCT02277769; CAF É - NCT02755649; CHRONOS - NCT02260986). Patients received subcutaneous DPL 300mg every 2 weeks (q2w) or placebo for 16 weeks (SOLO); DPL q2w + concomitant topical corticosteroids (TCS) or placebo + TCS for 1...
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Clinical Research and Epidemiology Source Type: research
The goal of this study was to predict clinical response to methotrexate (MTX) in atopic dermatitis patients, based on clinical characteristics and serum biomarkers We retrospectively included 78 AD patients treated with MTX in daily practice. Patients were classified as responders to MTX treatment if they achieved an Investigators ’ Global Assessment of 0-2 without the use of oral corticosteroids after 6 months of treatment. Clinical characteristics were extracted from the electronic patients file.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Innate Immunity and Inflammation Source Type: research
CONCLUSIONS: Because of the broad spectrum of clinical manifestations and the extreme diversity of disease, LCH remains a diagnostic dilemma. Morphological identification of LCH cells and positive immunochemical staining with CD1a, S100, and/or CD207 (Langerin) of lesional cells are necessary for a definitive diagnosis. PMID: 31456157 [PubMed - as supplied by publisher]
Source: World Journal of Pediatrics : WJP - Category: Pediatrics Authors: Tags: World J Pediatr Source Type: research
This study evaluated nemolizumab plus topical corticosteroids in patients with AD and severe pruritus and found a significant effect on cutaneous signs of AD (by EASI and IGA), plus a rapid reduction of pruritus.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research
Atopic dermatitis (AD) is the most common chronic pediatric skin disease, affecting an estimated 13% of children in the United States. Because access to specialized care is limited, and poorly controlled disease is marked by interval flares, many of these patients seek treatment in the emergency department (ED). In this setting, management often includes oral corticosteroids, antihistamines and antibiotics, an approach that provides short-term relief, but can potentiate rebound flares. The ED setting also carries several challenges related to lack of well-defined guidelines for managing flares, criteria for hospitalization...
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Atopic dermatitis (AD) patients uncontrolled on topical corticosteroids (TCS) wait variable durations before treatment escalation. While negative physical and psychosocial effects of this waiting are known, the economic burden is unknown. This real-world retrospective database study assessed whether time to therapy escalation among AD patients uncontrolled with topical agents impacts healthcare resource utilization (HCRU) or costs. Truven Health MarketScan Database data were analyzed from 01JAN2010 –30SEP2015 (identification period; IP).
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Interleukin (IL)-13 plays an important role in atopic dermatitis (AD) pathogenesis. Tralokinumab is a fully human monoclonal antibody that potently and specifically neutralizes IL-13. In this phase 2b study (NCT02347176), 204 adults with moderate-to-severe AD were randomized 1:1:1:1 to receive subcutaneous tralokinumab 45 mg, 150 mg, or 300 mg, or placebo, every 2 weeks for 12 weeks. Concomitant Class 3 (World Health Organization) topical corticosteroids were administered at least once daily during a 2-week run-in and as needed throughout the treatment and follow-up periods.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
More News: Children | Corticosteroid Therapy | Dermatitis | Dermatology | Health Management | Pediatrics | Skin